Octreotide acetate
Sandostatin (octreotide acetate) is an injectable prescription medication manufactured by Novartis Pharmaceuticals Corporation. It acts as a somatostatin analog, administered intravenously or subcutaneously in various strengths to help regulate hormone levels. This information was generated using AI and is provided for informational and research purposes only.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | Sandostatin (octreotide acetate) is an injectable prescription medication manufactured by Novartis Pharmaceuticals Corporation. It acts as a somatostatin analog, administered intravenously or subcutaneously in various strengths to help regulate hormone levels. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Octreotide acetate",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Octreotide acetate — ANDA 210317 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210317"
}
]
|
| identifier | ANDA210317 |
| issued | 2016-09-16 |
| keyword |
[
"drug",
"drug-manufacturers",
"drug-safety",
"fda",
"pharmaceuticals"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Octreotide acetate |
